Elsevier

The Lancet Haematology

Volume 8, Issue 10, October 2021, Pages e677-e678
The Lancet Haematology

Comment
Modelling the mortality of sickle cell disease in Africa

https://doi.org/10.1016/S2352-3026(21)00268-4Get rights and content

References (10)

There are more references available in the full text version of this article.

Cited by (1)

  • Effective therapies for sickle cell disease: are we there yet?

    2022, Trends in Genetics
    Citation Excerpt :

    The polymerization of HbS induces the formation of fragile, sticky, sickle-shaped RBCs, triggering a complex pathophysiology leading to the clinical manifestations of SCD [1,8]. In low-income regions where SCD is most prevalent, mainly Africa, at least half of SCD patients die before age 5 years [21–25]. Medical advances, including newborn screening, immunizations, antibiotics, and RBC transfusions with iron chelation, have greatly extended the lifespan of children with SCD in high-income countries [26].

View full text